Skin test evaluation of a novel peptide carrier–based vaccine, BM32, in grass pollen–allergic patients

Antzeko izenburuak

• Two years of treatment with the recombinant grass pollen allergy vaccine BM32 induces a continuously increasing allergen-specific IgG(4) response
  nork: Eckl-Dorna, Julia, et al.
  Argitaratua: (2019)
• Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32
  nork: Niederberger, Verena, et al.
  Argitaratua: (2018)
• Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope–based grass pollen allergy vaccine with allergen extract–based vaccines
  nork: Weber, Milena, et al.
  Argitaratua: (2017)
• Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy
  nork: Focke-Tejkl, Margarete, et al.
  Argitaratua: (2015)
• Immunotherapy With the PreS-based Grass Pollen Allergy Vaccine BM32 Induces Antibody Responses Protecting Against Hepatitis B Infection
  nork: Cornelius, Carolin, et al.
  Argitaratua: (2016)